Quantcast
Home > Quotes > AYTU
AYTU

Aytu BioScience, Inc. Common Stock (AYTU) Quote & Summary Data

$1.911
*  
0.101
5.58%
Get AYTU Alerts
*Delayed - data as of Jun. 18, 2019 13:37 ET  -  Find a broker to begin trading AYTU now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AYTU Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.91 / $ 1.92
1 Year Target
7
Today's High / Low
$ 1.95 / $ 1.83
Share Volume
125,132
50 Day Avg. Daily Volume
381,298
Previous Close
$ 1.81
52 Week High / Low
$ 7.80 / $ 0.68
Market Cap
31,838,015
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.85

Intraday Chart

Shares Traded

Share Volume:
125,132
50 Day Avg. Daily Volume:
381,298

Trading Range

The current last sale of $1.911 is 181.03% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.95 $ 7.80
 Low: $ 1.83 $ 0.68

Company Description (as filed with the SEC)

We are a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. We have multiple approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales force and an international distribution network with presence in approximately fifty countries. We are currently concentrating on hypogonadism, male infertility and, recently, insomnia and plan to expand into other indications for which we believe there are significant medical needs. We acquired exclusive U.S. rights to Natesto┬« (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel, and we launched Natesto in the U.S. with our direct sales force in late summer 2016.  ... More ...  



Risk Grade

Where does AYTU fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.85
Open Date:
Jun. 18, 2019
Close Price:
$ 1.81
Close Date:
Jun. 17, 2019


Consensus Recommendation

Analyst Info